Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Long-term study showed that vaccination protected paediatric renal transplant recipients from life-threatening varicella zoster virus.

Lindahl JK, Friman V, Ladfors SW, Hansson S, Andersson R, Jertborn M, Woxenius S.

Acta Paediatr. 2018 Dec;107(12):2185-2192. doi: 10.1111/apa.14375. Epub 2018 May 25.

2.

Induction of long term mucosal immunological memory in humans by an oral inactivated multivalent enterotoxigenic Escherichia coli vaccine.

Lundgren A, Jertborn M, Svennerholm AM.

Vaccine. 2016 Jun 8;34(27):3132-3140. doi: 10.1016/j.vaccine.2016.04.055. Epub 2016 Apr 28.

3.

Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.

Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM.

Vaccine. 2013 Feb 6;31(8):1163-70. doi: 10.1016/j.vaccine.2012.12.063. Epub 2013 Jan 7.

PMID:
23306362
4.

Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods.

Lundgren A, Kaim J, Jertborn M.

Vaccine. 2009 Jul 16;27(33):4529-36. doi: 10.1016/j.vaccine.2009.05.005. Epub 2009 May 27.

PMID:
19446596
5.

Effective control measures limited measles outbreak after extensive nosocomial exposures in January-February 2008 in Gothenburg, Sweden.

Follin P, Dotevall L, Jertborn M, Khalid Y, Liljeqvist JA, Muntz S, Qvarfordt I, Söderström A, Wiman A, Ahrén C, Osterberg P, Johansen K.

Euro Surveill. 2008 Jul 24;13(30). pii: 18937.

8.

T- and B-cell immune responses of patients who had undergone colectomies to oral administration of Salmonella enterica serovar Typhi Ty21a vaccine.

Kilhamn J, Lundin SB, Brevinge H, Svennerholm AM, Jertborn M.

Clin Diagn Lab Immunol. 2003 May;10(3):426-30.

9.

Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants.

Savarino SJ, Hall ER, Bassily S, Wierzba TF, Youssef FG, Peruski LF Jr, Abu-Elyazeed R, Rao M, Francis WM, El Mohamady H, Safwat M, Naficy AB, Svennerholm AM, Jertborn M, Lee YJ, Clemens JD; Pride Study Group.

Pediatr Infect Dis J. 2002 Apr;21(4):322-30.

PMID:
12075764
10.

[Control of methicillin resistant staphylococci at the Sahlgrenska hospital. Successful control program against MRSA outbreak].

Haglind E, Brantervik A, Friman S, Jertborn M, Rödjer S, Seeberg S.

Lakartidningen. 2001 Nov 21;98(47):5312-3. Swedish.

PMID:
11763628
11.

Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans.

Johansson EL, Wassén L, Holmgren J, Jertborn M, Rudin A.

Infect Immun. 2001 Dec;69(12):7481-6.

12.

[Infection a dreaded central venous catheter-related complication. A reminder of the significance of good aseptics is justified].

Hammarskjöld F, Linder LE, Larsson B, Jertborn M.

Lakartidningen. 2001 Aug 22;98(34):3510-4. Review. Swedish.

PMID:
11571791
13.

Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans.

Jertborn M, Nordström I, Kilander A, Czerkinsky C, Holmgren J.

Infect Immun. 2001 Jun;69(6):4125-8.

14.

Induction and distribution of intestinal immune responses after administration of recombinant cholera toxin B subunit in the ileal pouches of colectomized patients.

Kilhamn J, Brevinge H, Quiding-Järbrink M, Svennerholm AM, Jertborn M.

Infect Immun. 2001 May;69(5):3466-71. Erratum in: Infect Immun 2001 Oct;69(10):6564.

16.

Enterotoxin-specific immunoglobulin E responses in humans after infection or vaccination with diarrhea-causing enteropathogens.

Qadri F, Asaduzzaman M, Wennerås C, Mohi G, Albert MJ, Abdus Salam M, Sack RB, Jertborn M, McGhee JR, Sack DA, Holmgren J.

Infect Immun. 2000 Oct;68(10):6077-81.

17.

Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group.

Savarino SJ, Hall ER, Bassily S, Brown FM, Youssef F, Wierzba TF, Peruski L, El-Masry NA, Safwat M, Rao M, El Mohamady H, Abu-Elyazeed R, Naficy A, Svennerholm AM, Jertborn M, Lee YJ, Clemens JD.

J Infect Dis. 1999 Jan;179(1):107-14.

PMID:
9841829
18.
20.

Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine.

Jertborn M, Ahrén C, Holmgren J, Svennerholm AM.

Vaccine. 1998 Jan-Feb;16(2-3):255-60.

PMID:
9607039
21.
22.

Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults.

Savarino SJ, Brown FM, Hall E, Bassily S, Youssef F, Wierzba T, Peruski L, El-Masry NA, Safwat M, Rao M, Jertborn M, Svennerholm AM, Lee YJ, Clemens JD.

J Infect Dis. 1998 Mar;177(3):796-9.

PMID:
9498468
23.

Differential expression of tissue-specific adhesion molecules on human circulating antibody-forming cells after systemic, enteric, and nasal immunizations. A molecular basis for the compartmentalization of effector B cell responses.

Quiding-Järbrink M, Nordström I, Granström G, Kilander A, Jertborn M, Butcher EC, Lazarovits AI, Holmgren J, Czerkinsky C.

J Clin Invest. 1997 Mar 15;99(6):1281-6.

24.
25.

Local intravaginal vaccination of the female genital tract.

Wassén L, Schön K, Holmgren J, Jertborn M, Lycke N.

Scand J Immunol. 1996 Oct;44(4):408-14.

PMID:
8845036
26.

Immunological memory after immunization with oral cholera B subunit--whole-cell vaccine in Swedish volunteers.

Jertborn M, Svennerholm AM, Holmgren J.

Vaccine. 1994 Sep;12(12):1078-82.

PMID:
7998416
27.
28.

[Cholera: transmission, treatment, prevention. The 1991 epidemic is the first one in this century in Latin America].

Jertborn M.

Lakartidningen. 1992 Nov 11;89(46):3942-3, 3947. Swedish. No abstract available.

PMID:
1461009
29.

Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group.

Wiström J, Jertborn M, Ekwall E, Norlin K, Söderquist B, Strömberg A, Lundholm R, Hogevik H, Lagergren L, Englund G, et al.

Ann Intern Med. 1992 Aug 1;117(3):202-8.

PMID:
1616214
30.

[A new organization will lead and coordinate activities in travel medicine].

Sinclair R, Jertborn M, Norrbohm O, Mannheimer W.

Lakartidningen. 1992 Mar 25;89(13):1051-2. Swedish. No abstract available.

PMID:
1552803
31.
32.

An oral B subunit: whole cell vaccine against cholera.

Holmgren J, Svennerholm AM, Jertborn M, Clemens J, Sack DA, Salenstedt R, Wigzell H.

Vaccine. 1992;10(13):911-4.

PMID:
1471411
33.

[Prevention and treatment of traveler's diarrhea].

Svenungsson B, Jertborn M, Wiström J.

Nord Med. 1992;107(11):272-3. Review. Swedish.

PMID:
1448340
34.

Enterotoxin-producing bacteria isolated from Swedish travellers with diarrhoea.

Jertborn M, Svennerholm AM.

Scand J Infect Dis. 1991;23(4):473-9.

PMID:
1957131
35.

Infection with bacterial enteropathogens in Swedish travellers to South-East Asia--a prospective study.

Ahrén CM, Jertborn M, Herclik L, Kaijser B, Svennerholm AM.

Epidemiol Infect. 1990 Oct;105(2):325-33.

36.

Serum antibody responses to bacterial enteropathogens in Swedish travelers to south-east Asia.

Jertborn M, Ahrén C, Perlman DM, Kaijser B, Svennerholm AM.

Scand J Infect Dis. 1990;22(6):699-704.

PMID:
2284576
37.

Estimation of symptomatic and asymptomatic Salmonella infections.

Jertborn M, Haglind P, Iwarson S, Svennerholm AM.

Scand J Infect Dis. 1990;22(4):451-5.

PMID:
2218408
38.

Short-term self-treatment of travellers' diarrhoea with norfloxacin: a placebo-controlled study.

Wiström J, Jertborn M, Hedström SA, Alestig K, Englund G, Jellheden B, Norrby SR.

J Antimicrob Chemother. 1989 Jun;23(6):905-13.

PMID:
2668252
39.

[A promising new vaccine against typhoid fever].

Jertborn M.

Lakartidningen. 1989 Feb 22;86(8):631-2. Swedish. No abstract available.

PMID:
2921913
40.

Five-year immunologic memory in Swedish volunteers after oral cholera vaccination.

Jertborn M, Svennerholm AM, Holmgren J.

J Infect Dis. 1988 Feb;157(2):374-7. No abstract available.

PMID:
3335813
41.

IgG and IgA subclass distribution of antitoxin antibody responses after oral cholera vaccination or cholera disease.

Jertborn M, Svennerholm AM, Holmgren J.

Int Arch Allergy Appl Immunol. 1988;85(3):358-63.

PMID:
3350611
42.

A prospective study of serum antibody responses to enterotoxinogenic Escherichia coli in Swedish travellers.

Jertborn M, Svennerholm AM, Iwarson S.

Scand J Infect Dis. 1988;20(1):69-75.

PMID:
3283923
45.

Effect of neutralization of gastric acid on immune responses to an oral B subunit, killed whole-cell cholera vaccine.

Clemens JD, Jertborn M, Sack D, Stanton B, Holmgren J, Khan MR, Huda S.

J Infect Dis. 1986 Jul;154(1):175-8. No abstract available.

PMID:
3519789
46.

Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine.

Svennerholm AM, Jertborn M, Gothefors L, Karim AM, Sack DA, Holmgren J.

J Infect Dis. 1984 Jun;149(6):884-93.

PMID:
6736680
47.
48.

Current status of an oral B subunit whole cell cholera vaccine.

Svennerholm AM, Jertborn M, Gothefors L, Karim A, Sack DA, Holmgren J.

Dev Biol Stand. 1983;53:73-9.

PMID:
6873479
49.

Mecillinam versus cephaloridine for the treatment of acute pyelonephritis.

Trollfors B, Jertborn M, Martinell J, Norkrans G, Lidin-Janson G.

Infection. 1982 Jan;10(1):15-7. No abstract available.

PMID:
6279520
50.

Phlebitis induced by parenteral treatment with flucloxacillin and cloxacillin: a double-blind study.

Svedhem A, Alestig K, Jertborn M.

Antimicrob Agents Chemother. 1980 Aug;18(2):349-52.

Supplemental Content

Loading ...
Support Center